Six Key Takeaways on Dietary Supplement Regulation, 30 Years Post-DSHEA - Davis Wright Tremaine
The article reviews 30 years of dietary supplement regulation under DSHEA, highlighting ongoing FDA enforcement priorities: NDI notifications, structure/function claims, GMP compliance, warning letters, and emerging issues like NAC and CBD. No immediate regulatory changes, but increased scrutiny on mandatory product listing and adulteration.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; no immediate deadline but proactive review recommended within 90 days.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
No new regulation; the article reinforces existing FDA priorities and emerging trends (e.g., NAC, CBD) that may signal future enforcement shifts.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review current labeling and NDI notifications for compliance; monitor FDA guidance on NAC and CBD.
Deadline
Ongoing; no immediate deadline but proactive review recommended within 90 days.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- Warning Letters | FDA
- FDA Advisory No.2026-0735 || Public Health Warning on the Presence of Sildenafil Citrate in TURBO Maca and Clavo Huasca Dietary Supplement Capsules for Men with Lot Number 24TRB1102 - Food and Drug Administration - fda.gov.ph
- FDA Advisory No.2026-0162-A || Lifting the Advisory on the Registered Food Product LUXE SKIN BEAUTY TALKS L’ANNA Premium Oral Sunblock + Stem Cell Dietary Supplement “Public Health Warning Against the Purchase and Consumption of the Unregis - fda.gov.ph
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire